In vitro/in vivo comparisons in pulmonary drug delivery.
about
Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteersEvaluation of Aerosol Delivery of Nanosuspension for Pre-clinical Pulmonary Drug DeliveryMultivariate Analysis of Effects of Asthmatic Patient Respiratory Profiles on the In Vitro Performance of a Reservoir Multidose and a Capsule-Based Dry Powder InhalerAccessorized DPI: a Shortcut towards Flexibility and Patient Adaptability in Dry Powder Inhalation.Developing ways to evaluate in the laboratory how inhalation devices will be used by patients and care-givers: the need for clinically appropriate testing.Incentive device improves spacer technique but not clinical outcome in preschool children with asthma.Equivalent Lung Dose and Systemic Exposure of Budesonide/Formoterol Combination via Easyhaler and Turbuhaler.Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the long-acting muscarinic antagonist glycopyrronium.The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial.In vitro considerations to support bioequivalence of locally acting drugs in dry powder inhalers for lung diseases.Preclinical models for pulmonary drug delivery.In vitro and in vivo testing methods for respiratory drug delivery.Challenges in assessing regional distribution of inhaled drug in the human lungs.Challenges with developing in vitro dissolution tests for orally inhaled products (OIPs).Bioequivalence of inhaled drugs: fundamentals, challenges and perspectives.Delivering antibiotics to the lungs of patients with ventilator-associated pneumonia: an update.Extra-fine particle inhaled corticosteroids, pharma-cokinetics and systemic activity in children with asthma.Pharmacodynamic and pharmacokinetic assessment of fluticasone furoate + vilanterol for the treatment of asthma.Scientific Rationale for Determining the Bioequivalence of Inhaled Drugs.The Impact of Inspiratory Flow Rate on Drug Delivery to the Lungs with Dry Powder Inhalers.Fluticasone uptake across Calu-3 cells is mediated by salmeterol when deposited as a combination powder inhaler.Dry powder aerosols to co-deliver antibiotics and nutrient dispersion compounds for enhanced bacterial biofilm eradication.Implementation of design of experiments approach for the micronization of a drug with a high brittle-ductile transition particle diameter.In vitro/in vivo correlation and modeling of emitted dose and lung deposition of inhaled salbutamol from metered dose inhalers with different types of spacers in noninvasively ventilated patients.Good Cascade Impactor Practice (GCIP) and considerations for "in-use" specifications.Product lifecycle approach to cascade impaction measurements.Aerosol particle size does not predict pharmacokinetic determined lung dose in children.Inhaled Treprostinil Drug Delivery During Mechanical Ventilation and Spontaneous Breathing Using Two Different Nebulizers.Airway geometry, airway flow, and particle measurement methods: implications on pulmonary drug delivery.Pharmacological and toxicological assessment of innovative self-assembled polymeric micelles as powders for insulin pulmonary delivery.
P2860
Q28272841-A72259D6-4D69-4EA9-AB96-2A8E7607E5DCQ28396497-5FFDD13A-CB4F-420F-8285-4C4D52D26DC2Q30390980-7119F573-CEEF-40C1-B434-9186AE44ADB1Q33468788-EC241031-B27F-4833-9E1B-755996579F1BQ34265177-E07CE72B-C01E-4DFF-AD39-D1335019DC83Q35680824-ABE653EA-CE82-4A5B-BDA5-4F23B96CD9F9Q36396728-1B631B4D-18A5-47A0-89C7-67FDC4A2E642Q37077219-C3D8ADDB-3FB2-4820-8ED8-FBC306A003CBQ37428235-236C24C2-7650-4156-AB4B-4A06F83ADA0DQ37507766-5732EEB7-8C88-4E1C-B6B1-D242C83836ADQ37620365-5A284ABF-5708-4F0A-A3D1-E1A747B4C683Q37822755-46170244-CDF9-417A-9260-9407BCC48EABQ37873491-D5B249B3-7CBB-4C50-B01C-3FC9AEEBAD03Q38026512-CC161378-B6CC-49AF-924F-155339EDCBBBQ38084738-EC15CC5B-64F1-48A7-B323-229D9EB848C7Q38102781-E8D87960-B5CD-439D-A78D-6BB685EC550FQ38584947-43E7A36A-2468-4756-AEC8-1334D81EFB6EQ38851423-AE069A2B-0261-44B1-9856-5119CB47B482Q38909886-FCA109F7-BBFA-46EB-BBCE-67F8FE1D4F6AQ38980035-644C3C96-5F1D-4C3F-B416-AE779B161AABQ39135769-2A982160-EFE8-4621-8A04-448E64626D7AQ39143592-98CD0D70-DF32-4DBE-A825-6D16BEAA0536Q39242932-C89CC3AA-282A-4CF3-99BD-411AB8E59415Q40274049-0A2590AE-400B-47BE-B856-70E4E0CBCC9CQ41994333-F0C1196A-1097-4812-8706-134842AC71A1Q42012934-F5CB2CAC-2C9F-43BB-BFAB-BA8DC8579254Q46196254-C34DBFF5-5CED-4402-9F9B-CF4866263536Q47303437-BF7AB8ED-8682-49C1-A22B-59CE77BD2091Q47337936-35DF9890-874B-4E8A-82E1-490F9351C029Q51596702-D0B6A0DC-CF25-497B-A560-9028C8E940B8
P2860
In vitro/in vivo comparisons in pulmonary drug delivery.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
In vitro/in vivo comparisons in pulmonary drug delivery.
@en
In vitro/in vivo comparisons in pulmonary drug delivery.
@nl
type
label
In vitro/in vivo comparisons in pulmonary drug delivery.
@en
In vitro/in vivo comparisons in pulmonary drug delivery.
@nl
prefLabel
In vitro/in vivo comparisons in pulmonary drug delivery.
@en
In vitro/in vivo comparisons in pulmonary drug delivery.
@nl
P356
P1476
In vitro/in vivo comparisons in pulmonary drug delivery.
@en
P2093
Stephen P Newman
P356
10.1089/JAMP.2007.0643
P50
P577
2008-03-01T00:00:00Z